# A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery

> **NCT00718081** · PHASE2 · COMPLETED · sponsor: **Talphera, Inc** · enrollment: 88 (actual)

## Conditions studied

- Major Upper or Lower Abdominal Surgery

## Interventions

- **DRUG:** Oral sufentanil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00718081
- **Lead sponsor:** Talphera, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2015-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00718081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00718081, "A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00718081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*